Journal article
The Aetiological Role of Human Papillomavirus in Oesophageal Squamous Cell Carcinoma: A Meta-Analysis
SS Liyanage, B Rahman, I Ridda, AT Newall, SN Tabrizi, SM Garland, E Segelov, H Seale, PJ Crowe, A Moa, CR MacIntyre
Plos One | PUBLIC LIBRARY SCIENCE | Published : 2013
Abstract
Background:The aetiological role of human papillomavirus (HPV) in oesophageal squamous cell carcinoma (OSCC) has been widely researched for more than three decades, with conflicting findings. In the absence of a large, adequately powered single case-control study, a meta-analysis of all available case-control studies is the most rigorous way of identifying any potential association between HPV and OSCC. We present the first global meta-analysis of case-control studies investigating the role of HPV in OSCC.Methods:Case-control studies investigating OSCC tissue for presence of HPV DNA were identified. 21 case-control studies analyzing a total of 1223 cases and 1415 controls, met our inclusion ..
View full abstractGrants
Awarded by Merck
Funding Acknowledgements
ATN holds an NHMRC Training Fellowship (630724 - Australian Based Public Health Fellowship) and has previously received research funding for other projects from a manufacturer of HPV vaccine. HS currently holds a National Health and Medical Research Council (NHMRC) Training Fellowship (1012631) - Australian Based Public Health Fellowship). SG has received advisory board fees and grants support from CSL and GlaxoSmithKline, and lecture fees from Merck, GSK and Sanofi Pasteur; in addition, she has also received funding through her institution to conduct HPV vaccine studies for MSD and GSK. She is a member of the Merck Global Advisory Board as well as the Merck Scientific Advisory Committee for HPV. CRM has been on advisory boards for Merck, GSK and Pfizer for vaccines other than HPV. She has received funding for investigator-driven research on HPV vaccine from Merck. She has received funding for investigator driven research for other vaccines from GSK, CSL Biotherapies and Pfizer. The other authors have no competing interests to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.